More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13

CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease.“In the past several years, there have been a number of formulations of infliximab that have met criteria for what is known as biosimilarity,” Stephen B. Hanauer, MD, the Clifford Joseph Barborka Professor of Medicine at Northwestern University Feinberg School of Medicine, told Healio. “One of those formulations is CT-P13.”HeRead More